{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:52:18Z","timestamp":1794135138922,"version":"4.8.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>\n            Dyslipidemia is common in chronic kidney disease (CKD). Despite statins, many patients fail to adequately lower lipids and remain at increased risk of cardiovascular disease. Selective ET\n            <jats:sub>A<\/jats:sub>\n            (endothelin-A) receptor antagonists reduce cardiovascular disease risk factors. Preclinical data suggest that ET\n            <jats:sub>A<\/jats:sub>\n            antagonism has beneficial effects on circulating lipids. We assessed the effects of selective ET\n            <jats:sub>A<\/jats:sub>\n            antagonism on circulating lipids and PCSK9 (proprotein convertase subtilisin\/kexin type 9) in CKD. This was a secondary analysis of a fully randomized, double-blind, 3-phase crossover study. Twenty-seven subjects with predialysis CKD on optimal cardio- and renoprotective treatment were randomly assigned to receive 6 weeks dosing with placebo, the selective ET\n            <jats:sub>A<\/jats:sub>\n            receptor antagonist, sitaxentan, or long-acting nifedipine. We measured circulating lipids and PCSK9 at baseline and then after 3 and 6 weeks. Baseline lipids and PCSK9 did not differ before each study phase. Whereas placebo and nifedipine had no effect on lipids, 6 weeks of ET\n            <jats:sub>A<\/jats:sub>\n            antagonism significantly reduced total (\u221211\u00b11%) and low-density lipoprotein\u2013associated (\u221220\u00b13%) cholesterol, lipoprotein (a) (\u221216\u00b12%) and triglycerides (\u221220\u00b14%); high-density lipoprotein\u2013associated cholesterol increased (+14\u00b12%),\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05 versus baseline for all. Additionally, ET\n            <jats:sub>A<\/jats:sub>\n            receptor antagonism, but neither placebo nor nifedipine, reduced circulating PCSK9 (\u221219\u00b12%;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001 versus baseline;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.05 versus nifedipine and placebo). These effects were independent of statin use and changes in blood pressure or proteinuria. Selective ET\n            <jats:sub>A<\/jats:sub>\n            antagonism improves lipid profiles in optimally-managed patients with CKD, effects that may occur through a reduction in circulating PCSK9. ET\n            <jats:sub>A<\/jats:sub>\n            receptor antagonism offers a potentially novel strategy to reduce cardiovascular disease risk in CKD.\n          <\/jats:p>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT00810732.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.119.12919","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T09:00:37Z","timestamp":1560157237000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) in Patients With Chronic Kidney Disease"],"prefix":"10.1161","volume":"74","author":[{"given":"Tariq E.","family":"Farrah","sequence":"first","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"},{"name":"Department of Renal Medicine, Royal Infirmary of Edinburgh (T.E.F., P.J.G., N.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Anand","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Gallacher","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"},{"name":"Department of Renal Medicine, Royal Infirmary of Edinburgh (T.E.F., P.J.G., N.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kimmitt","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Carter","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Dear","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Mills","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Webb","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Dhaun","sequence":"additional","affiliation":[{"name":"From the University\/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, University of Edinburgh, Queen\u2019s Medical Research Institute (T.E.F., A.A., P.J.G., R.K., E.C., J.W.D., N.L.M., D.J.W., N.D.)"},{"name":"Department of Renal Medicine, Royal Infirmary of Edinburgh (T.E.F., P.J.G., N.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62004-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006091006"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.11.014"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-7-201304020-00004"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702027200"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.07.023"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020912"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121256"},{"key":"e_1_3_4_15_2","first-page":"819","article-title":"Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol.","volume":"146","author":"Kowala MC","year":"1995","unstructured":"Kowala, MC, Rose, PM, Stein, PD, Goller, N, Recce, R, Beyer, S, Valentine, M, Barton, D, Durham, SK. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol. 1995;146:819\u2013826.","journal-title":"Am J Pathol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.113068"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008050482"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.967406"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2415-y"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080830"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.167486"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.132670"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2014.081182"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12064"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018531"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146920"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308811"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31652-0"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309920"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700437-JLR200"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.5.1313"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.986"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2762"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00482.2011"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep43152"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61919"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201X.1997.00212.x"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.05.019"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00477.2002"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.11.026"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht309.P4166"},{"key":"e_1_3_4_44_2","unstructured":"US National Library of Medicine. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762850. Accessed April 23 2019."},{"key":"e_1_3_4_45_2","unstructured":"US National Library of Medicine. Randomized Double-Blind Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01613118. Accessed January 31 2019"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.12919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:58:54Z","timestamp":1715594334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.119.12919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.119.12919"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.119.12919","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}